Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC) but resistance to tyrosine kinase inhibitors (TKIs) develops within 10-14 months.
• Mechanisms of resistance include T790M mutation, MET amplification, HGF overexpression, IGF receptor signaling, and transformation to small cell lung cancer.
• Current strategies to overcome resistance, such as irreversible EGFR inhibitors or combination therapies, have yielded limited success.

Observation:

• This report details a unique case of a patient with NSCLC who experienced acquired resistance to erlotinib (an EGFR-TKI).
• Remarkably, the resistance reverted twice, with significant clinical improvement observed after each instance.
• This suggests a potential for repeated TKI treatment in specific scenarios.

Findings:

• The patient demonstrated a reversible resistance to erlotinib, challenging the notion of permanent TKI resistance.
• The reversion of resistance occurred twice, indicating a dynamic response to EGFR-TKI therapy.
• Each instance of resistance reversion led to a notable improvement in patient outcomes.

Implications:

• This case suggests that repeated treatment with EGFR-TKIs might be a viable therapeutic strategy for NSCLC patients who develop acquired resistance.
• Further investigation into the mechanisms underlying this reversible resistance is warranted.
• This finding could lead to revised treatment paradigms for managing acquired resistance in EGFR-mutated NSCLC.